An implantable left ventricular assist device, which provides self-regulating circulatory support for end-stage heart disease, serving as a mechanical bridge while Pt awaits a heart transplant
Mentioned in ?
References in periodicals archive ?
He has served as vice president of coil and extrusion coatings at Valspar, as director of building products and in various technical roles at Glidden, and as business development manager at Novacor Chemical.
Both revenue recognized on implant kits and peripheral product sales decreased in 2006 due to WorldHeart's decision to significantly reduce its commercial efforts for its first-generation, Novacor LVAS, product and a shifting in the market place toward the next generation products.
The Novacor Left Ventricular Assist System (LVAS) will now be available, through the study, to patients who previously did not have access to this potentially life-saving therapy.
In a subgroup analysis of 87 patients who received a Novacor left ventricular assist system (LVAS) when they were clinically ineligible for a heart transplant because of a relative contraindication, about two-thirds subsequently improved sufficiently on the device to become eligible for listing and went on to receive a transplanted heart, James B.
World Heart Corporation, Oakland, CA announced the US Food and Drug Administration (FDA) has approved it's Pre-market Approval Supplement submission to incorporate several engineering enhancements to the implanted and external components of the Novacor LVAS (left ventricular assist system).
A new joint marketing accord between Novacor Chemicals and RheTech Inc.
Novacor Chemicals polypropylene business announced that prices on all grades of Adpro polypropylene and TPO resins will increase five cents (U.
Novacor relies on process research and development, focused to identify and commercialize innovations that improve the cost-performance balance of its products, as one source of that competitive advantage.
Oyer was working as a resident at Stanford in the lab of Norman Shumway, MD, PhD, the father of heart transplantation, in the early 1970s when he first met Portner, who had founded a small company, Novacor Medical Corp.
WorldHeart has reduced manufacturing, selling and administrative costs primarily associated with its Novacor LVAS.
World Heart Corporation, Oakland, CA, announced that, subject to approval of the US Food and Drug Administration (FDA), it intends to conduct a pivotal trial in approximately 30 US centers in which the Novacor LVAS is compared to HeartMate XVE LVAS in use as destination therapy for patients suffering from irreversible left ventricular failure who are not transplant candidates.
Both Fina Oil & Chemical and Novacor Chemicals have previously revealed their development efforts in this arena (PT, June '93, p.